Tralokinumab-ldrm (Adbry) is now approved for the treatment of moderate to severe atopic dermatitis in adults whose disease has not been controlled by topical therapies.Nurses and NPs should teach patients how to administer the drug subcutaneously and that more than one injection is needed to fulfill the prescribed dose.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/01.NAJ.0000830724.28193.9f | DOI Listing |
Publication Analysis
Top Keywords
atopic dermatitis
8
drug atopic
4
dermatitis tralokinumab-ldrm
4
tralokinumab-ldrm adbry
4
adbry approved
4
approved treatment
4
treatment moderate
4
moderate severe
4
severe atopic
4
dermatitis adults
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!